Clinical Trial

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Evaluating the efficacy and safety of adebrelimab in combination with apatinib, gemcitabine and cisplatin in the neoadjuvant treatment of patients with biliary tract malignancies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-21; most recent amendment 2024-04-27.
Status change: Not Yet Recruiting → Recruiting 2024-02-27
Trial Details
NCT Number NCT06181032
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Biliary Tract Malignancies
Enrollment 35 participants
Start Date 2023-12-23
Primary Completion 2029-02-23 (estimated)
Study Completion 2029-02-23 (estimated)
Updated on ClinicalTrials.gov 2024-04-30